Riverside Partners Portfolio Company J-Pac Names New CEO

    BOSTON, July 15 /EMWNews/ -- Riverside Partners, a Boston based

private equity firm focusing on healthcare and technology businesses, is

pleased to announce that The J-Pac and Doyen Medipharm Group ("JPDM" or the

"Company"), a leader in contract manufacturing and packaging machinery for

the medical device and pharmaceutical industries, has named Dr. P. Richard

Eagling as the Company's new Chief Executive Officer and a board member.

Richard succeeds Bill McLaughlin, who led JPDM successfully for the past 8

years. Mr. McLaughlin will remain active with the Group as its Vice

Chairman and a member of the board of directors.



    Dr. Eagling brings to J-Pac and Doyen Medipharm 30 years of industry

experience in the medical device, diagnostic, life science and

biopharmaceutical fields. Dr. Eagling has been responsible for leading

large divisions of several companies including Ciba Corning Diagnostics,

Oridion Medical, Integrated Biosystems and most recently Stedim Biosystems.

Additionally, Dr. Eagling previously served as the President and CEO of

Gamera Bioscience.



    "We believe Richard's experience and proven success with global

companies, working in organizations both larger and smaller than J-Pac,

will help us continue to capitalize on the tremendous opportunities for

growth ahead of us. We are sure that his commitment, integrity, and

interpersonal style will fit extremely well with the culture and values of

our entire team," said Brian Guthrie, a General Partner at Riverside

Partners and Chairman of the Board of J-Pac.



    "I am extremely excited to build upon the great medical manufacturing

platform that Bill McLaughlin and his team has created at J-Pac and Doyen

Medipharm and am looking forward to leading the Company's next phase of

growth. We will continue to focus on providing high quality advanced drug

delivery and related medical products to the world's leading OEMs," said

Dr. Eagling.

    About J-Pac and Doyen Manufacturing



    Headquartered in Somersworth, NH, J-Pac is a leading contract

manufacturer and equipment maker for medical device and biopharmaceutical

OEMs. J-Pac's contract manufacturing division specializes in medical

devices, medical packaging and trays, and advanced medical device and drug

delivery systems. Through its Doyen Division, J-Pac also provides precision

high-volume production equipment to medical device and biopharmaceutical

OEMs around the world.



    About Riverside Partners



    Founded in 1989, Riverside Partners is a middle market private equity

firm currently investing Riverside Fund III, L.P. The fund focuses on

growth-oriented companies in the healthcare and technology industries.

Riverside is particularly experienced at partnering with founders, owners

and management teams and it brings substantial domain expertise and

operating experience to its portfolio companies. The partners at Riverside

have managed more than $500 million in investments in over 50 companies. We

are currently focused on companies with revenues between $20 - $200 million

and with $5 - $25 million of EBITDA.